oritavancin
Sign in to saveAlso known as LY-333328, Chlorobiphenyl-chloroeremomycin
Oritavancin, sold under the brand name Orbactiv among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin.
Key facts
- Drug.image
- Oritavancin.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Orbactiv, others
- Drug.MedlinePlus
- a614042
- Drug.DailyMedID
- Oritavancin
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- J01
- Drug.ATC_suffix
- XA05
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 171099-57-3
- Drug.PubChem
- 16131319
- Drug.DrugBank
- DB04911
- Drug.ChemSpiderID
- 31149229
- Drug.UNII
- PUG62FRZ2E
- Drug.KEGG
- D05271
- Drug.ChEBI
- 82699
via Wikipedia infobox
Research
545 papers- Oritavancin.2006
- Oritavancin: A Novel Lipoglycopeptide.The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists · 2016
- Oritavancin: A Long-Half-Life Lipoglycopeptide.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
- Antibiotic penetration into bone and joints: An updated review.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2019
- Oritavancin for acute bacterial skin and skin structure infections.Expert opinion on pharmacotherapy · 2015
via PubMed
~4 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- ''In vitro'' activity
- Mechanism
- Synergism
- Spectrum of Activity
- History
- References
Oritavancin, sold under the brand name Orbactiv among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin.
The US Food and Drug Administration and the European Medicines Agency approved oritavancin for treatment of acute bacterial skin and skin structure infections.
Excerpted from Wikipedia’s “oritavancin” article, available under the CC BY-SA 4.0 licence.